Lilly Inks Deal With BioMS For Phase III Multiple Sclerosis Compound
Collaboration valued at $497 million plus royalties aims to develop, commercialize synthetic peptide MBP8298, Lilly tells “The Pink Sheet” DAILY.
Collaboration valued at $497 million plus royalties aims to develop, commercialize synthetic peptide MBP8298, Lilly tells “The Pink Sheet” DAILY.